FDA Approval of Adjuvant Pembrolizumab for NSCLC | IASLC
On January 26, 2023, the US FDA granted approval for pembrolizumab, an anti-PD-1 antibody, as adjuvant therapy for patients with resected NSCLC. In this episode …
On January 26, 2023, the US FDA granted approval for pembrolizumab, an anti-PD-1 antibody, as adjuvant therapy for patients with resected NSCLC. In this episode …
This episode of Lung Cancer Considered covers the recently completed European Lung Cancer Congress held in Prague. Host Dr. Stephen Liu discusses the important …
More details about WCLC 2024 abstract submission will be available in November 2023.
The agency also granted approval to amivantamab as a treatment for patients with locally advanced or metastatic NSCLC with EGFR exon 20 insertion mutations who…
Key points of this webinar encompass significant research findings presented at the recent Targeted Therapies in Lung Cancer (TTLC) conference held in Santa Mon …
Small cell lung cancer is a challenging subtype of lung cancer to treat because most patients present with extensive stage disease. Unlike non-small cell lung…
Biomarker testing is essential in lung cancer care, allowing for personalized diagnosis and treatment. Survey closes March 23, 2024.
Biomarker testing is essential in lung cancer care, allowing for personalized diagnosis and treatment. Survey closes March 23, 2024.
Advocate Angus Pratt explores the issues patients face while researching their disease when inaccurate and out-of-date information is everywhere.
Key points of this webinar encompass significant research findings presented at the recent Targeted Therapies in Lung Cancer (TTLC) conference held in Santa Mon …
Biomarker testing is essential in lung cancer care, allowing for personalized diagnosis and treatment. Survey closes March 23, 2024.